LONHALA MAGNAIR Rx
Generic Name and Formulations:
Glycopyrrolate 25mcg/mL; oral soln for inhalation.
Indications for LONHALA MAGNAIR:
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
For oral inhalation use only with Magnair device. Administer at the same time of the day (AM + PM). Inhale contents of one vial (25mcg) twice daily.
Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Labor & delivery. Pregnancy. Nursing mothers.
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Dyspnea, urinary tract infection, wheezing, upper respiratory tract infection, nasopharyngitis, peripheral edema, fatigue; paradoxical bronchospasm, hypersensitivity reactions.
Kit—60 vials (w. one Magnair device)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age